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C isplatin (cis-diamminedicloroplatinum) is an 
antineoplastic drug used in the treatment of a variety of 
cancers, especially head-and-neck cancer. Its ototoxicity, 
however, has been noted as a common side-effect which 
limits its use and causes significant morbidity. Aim: to assess 
distortion-product otoacoustic emissions (DPOAE) and 
brainstem evoked response audiometry (BERA) sensitivity 
to detect secondary ototoxicity caused by different doses 
and means of administration of cisplatin in rats. Study 
Design: Experimental. Material and Methods: Male Wistar 
rats were intraperitoneally (i.p.) injected with 24 mg/kg 
cisplatin, divided into three equal doses (8mg/kg) or a single 
i.p. injection of 16 mg/kg. The animals were evaluated by 
distortion product otoacoustic emission (DPOAE) or brainstem 
evoked response audiometry (BERA) on the 3rd and 4th days 
after the cisplatin injection. Results: Treatment with cisplatin 
24 mg/kg resulted in significant DPOAE decrease and it raised 
the BERA electrophysiological threshold. The 16mg/kg dose 
could not significantly reduce the DPOAE amplitude, but it 
raised the animals’ hearing thresholds - detected by the BERA. 
Conclusion: In rats, BERA was more sensitivity than DPOAE 
at detecting cisplatin-induced ototoxicity in rats considering 
different doses and means of administration.
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INTRODUCTION
Cisplatin (cis-diamine-dichloroplatinum - CDDP) 
is a chemothepeutic drug frequently used to treat many 
types of cancer, especially those in the head and neck1. Its 
side effects include ototoxicity, nephrotoxicity, medullary 
suppression and GI disorders2. These types of toxicity can 
interfere with treatment as it reduces treatment dosage, 
frequence and duration in many patients3.
The incidence of cisplatin toxicity can vary between 
4 and 50%4-6. The degree of hearing loss depends on the 
dose and frequency of drug administration. Bolus doses 
in adults cause more intense ototoxic damage7. Other 
factors which influence the degree of hearing loss include 
age (children and the elderly are more susceptible), more 
chemotherapeutic cycles, previous use of other drugs 
such as furosemide and ethacrynic acid, associated renal 
dysfunction and individual susceptibility8,9. Moreover, 
because of cisplatin buildup in the body along treatment 
years, a progressive hearing loss can remain even after 
treatment suspension10.
Animal studies have shown that cisplatin causes 
degeneration to the organ of Corti, with complete or par-
tial loss of outer hair cells and, sporadically, that of inner 
hair cells 11,12. Adding to the ototoxic effects of cisplatin on 
the organ of Corti, there is evidence of stria vascularis12-22,, 
spiral ganglion12,17-19,23,24 and Reissner vestibular membrane 
involvement12,25,26.
Different doses and means of administration are 
used in order to achieve ototoxic effects in rodents. The 
most commonly used means of administration is intraperi-
toneal (IP). It is well known that cisplatin’s chronic effects 
are less intense than its acute counterparts15.
There are many ways to assess hearing involvement 
in lab animals, varying from simple methods such as the 
Preyer’s effect27, all the way to more sophisticated and 
expensive methods such as the brainstem evoked audi-
tory potentials28-30, electrococleography12,17 and evoked 
otoacoustic emissions2,30-32. Evoked Otoacoustic Emissions 
(EOA) and brainstem evoked auditory potentials (BEAP), 
with broad use in clinical practice, are the ultimately 
more often employed methods to study cisplatin-induced 
ototoxicity in rodents.
The goal of the present investigation was to assess 
distortion product evoked otoacoustic emissions (DPEO-
AE) and brainstem evoked auditory potentials (BEAP) in 
the detection of ototoxicity secondary to different doses 
and means of administering cisplatin in rats.
MATERIALS AND METHODS
We used male Wistar rats weighing between 200 
and 348g, kept in cages with free access to food and water, 
natural cycles of sleep and awake periods, and handled 
according to the standards advocated by the Brazilian 
College of Experimentation with Animals (COBEA), whi-
ch can be found at www.cobea.org.br. This project was 
submitted to and approved by the Ethics in Research with 
Small Animals Committee (CEPA) and was approved under 
protocol number 28/05.
Animals with signs of external ear disorders, such 
as: external acoustic meatus hyperemia and edema, tumors 
or impacted ear wax; animals with middle ear disorders 
such as tympanic membrane opacification, bulging and 
hyperemia or perforations; animals without distortion 
product otoacoustic emissions in any of the frequencies 
investigated (3, 4, 6 and 8 kHz), before drug injection; 
animals with electrophysiological potential greater than 
10dB NA - seen at the brainstem evoked auditory potential, 
before drug injection, were all taken off the study.
The drugs used in the study were:
Cisplatin (Cisplatex® -Eurofarma 50 mg. Brazil): 
Freeze-dried powder for injectable solution. Preparation: 
50 mg of the powder diluted in 50 ml of saline solution, 
making up a final concentration of 1 mg/ml;
Saline solution 0.9%;
Ketamine (Vetarnacol®- König Pharmaceutics 
50mg/ml. Brazil);
Xylazine (Kensol®- König Pharmaceutics 20 mg/
ml. Brazil).
The animals were broken down into 12 groups, 
listed as follows; here n means the number of rats in 
each group:
Group 1 (CDDP 24 D3 EOAPD) (n=11): cisplatin-
treated rats at the dose of 8 mg/kg/day for 3 consecutive 
days (a total of 24 mg/kg) and assessed before treatment 
(DO) and three days after its onset (D3) by means of dis-
tortion product evoked otoacoustic emissions (DPEOAE).
Group 2 (C 24 D3 DPEOAE) (n=6): rats treated with 
saline solution at the dose of 8 ml/kg/day for 3 consecutive 
days (total of 24 ml/kg) and assessed before treatment (D0) 
and three days (D3) after its onset by distortion product 
evoked otoacoustic emissions (DPEOA).
Group 3 (CDDP 24 D4 DPEOAE) (n=8): rats trea-
ted with cisplatin at the dose of 8 mg/kg/day for three 
consecutive days (total of 24 mg/kg) and assessed before 
treatment (D0) and four days (D4) after its onset by dis-
tortion product evoked otoacoustic emissions (DPEOAE).
Group 4 (C 24 D4 DPEOAE) (n=6): rats treated with 
saline solution at the dose of 8 ml/kg/day for 3 consecutive 
days (total of 24 ml/kg) and assessed before treatment (D0) 
and on the 4th day after its onset (D4) distortion product 
evoked otoacoustic emissions (DPEOAE).
Group 5 (CDDP 16 D3 DPEOAE) (n=12): rats 
treated with cisplatin in a single dose of 16 mg/kg/day, 
assessed before injection (D0) and three days after (D3) its 
onset by distortion product evoked otoacoustic emissions 
(DPEOAE).
Group 6 (C 16 D3 DPEOAE) (n=5): rats treated with 
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saline solution at a single dose of 16 ml/kg/day, assessed 
before treatment (D0) and three days (D3) after its on-
set by distortion product evoked otoacoustic emissions 
(DPEOAE).
Group 7 (CDDP 16 D4 DPEOAE) (n=7): rats injected 
with cisplatin in a single dose of 16 mg/kg/day, assessed 
before treatment (D0) and four days (D4) after its onset 
by  distortion product evoked otoacoustic emissions 
(DPEOAE).
Group 8 (C 16 D4 DPEOAE) (n=6): rats injected 
with saline solution at a single dose of 16 ml/kg/day, as-
sessed before injection (D0) and four days (D4) after its 
onset by distortion product evoked otoacoustic emissions 
(DPEOAE).
Group 9 (CDDP 24 BEAP) (n=11): rats injected with 
cisplatin at the dose of 8 mg/kg/day for 3 consecutive 
days (total of 24 mg/kg) and assessed before treatment 
(D0) and three (D3) and four (D4) days after its onset by 
brainstem evoked auditory potentials (BEAP).
Group 10 (C 24 BEAP) (n=7): rats injected with sa-
line solution at the dose of 8 ml/kg/day for 3 consecutive 
days (total of 24 ml/kg) an assessed before the injection 
(D0), three (D3) and four (D4) days after its onset by 
brainstem evoked auditory potentials (BEAP).
Group 11 (CDDP 16 BEAP) (n=12): rats injected 
with a single 16mg/kg/day dose of cisplatin and assessed 
before treatment (D0), three (D3) and four (D4) days 
after its onset by means of brainstem evoked auditory 
potentials (BEAP).
Group 12 (C 16 BEAP) (n=8): rats injected with a 
single 16ml/kg/day dose of saline solution and assessed 
before injection (D0), three (D3) and four (D4) days after 
its onset by brainstem evoked auditory potentials (BEAP).
The entire procedure is based on two experiments:
In experiment 1, Wistar rats were submitted to 
profound anesthesia with 50mg/kg ketamine plus 10mg/
kg xylazine. Their ears were previously examined through 
otoscopy in order to take off the study those animals with 
signs of middle or external ear disorders, as per descri-
bed in the exclusion criteria. Those animals with normal 
otoscopy were submitted to distortion product evoked 
otoacoustic emissions (DPEOAE), immediately before drug 
administration. In the 8ml/kg cisplatin for 3 consecutive 
days and 8 ml/kg for 3 days of saline solution groups, the 
drugs were intraperitoneally injected immediately after the 
auditory evaluation. In the two subsequent days, after wei-
ghing the rats again, they were again injected with 8mg/
kg of cisplatin or 8ml/kg of saline solution, in order to 
result in a final dose of 24mg/kg and 24ml/kg, respectively. 
Twenty four (D3) or 48h (D4) after the last injection, the 
rats were once again anesthetized and another otoscopy 
was carried out in order to exclude those which had ac-
quired middle or external ear disorders during the drug 
administration period, and were then submitted to a new 
auditory evaluation by means of DPEOAE. In the groups 
which received 16mg/kg of intraperitoneal cisplatin and 
16ml/kg of saline solution, we used a Kd Scientific Series 
100 infusion pump in order to fix the infusion time in 30 
minutes. When necessary, a new dose of anesthetics was 
used. Hearing assessment was also carried out on the third 
(D3) and fourth (4D) days after drug injection.
In experiment 2, the animals were submitted to the 
same anesthesia, otoscopy and drug injection procedures 
reported for the first experiment. Auditory assessment 
was carried out by means of a BEAP (Brainstem Evoked 
Auditory Potential), and the same group of animals was 
submitted to testing immediately before and on the third 
and fourth days after drug administration.
DPEOAE were captured by the MADSEN Capella 
- GN Otometrics Otoacoustic Emissions device in a silent 
room. The rats were anesthetized and a probe was cou-
pled to their right external auditory canal (probes used in 
newborn babies). The stimulus was made up of 2 pure 
sounds (F1 and F2), which F1/F2 frequency ratio was 1.22. 
Stimuli intensity was fixed in 70 dB SPL. We analyzed a 
total of 1000 stimuli. The resulting otoacoustic emissions 
were assessed in the frequencies of 3, 4, 6 and 8 kHz. 
DPEOAE present were considered when we achieved a 
signal/noise ratio of at least 6 dB SPL, according to the 
technical specifications on the device used. 
In order to perform the BEAP, we used the EP 25 
device from Interacoustic, in a silent environment. With 
the animals properly anesthetized, platinum subdermal 
electrodes were placed on the vertex (positive), right retro-
auricular region (negative) and on the nasal tip (ground). 
ER-3A insertion phones were coupled to a probe (used to 
assess the hearing of newborns) and introduced into the 
rat’s external right auditory canal. The stimuli used were 
rarefaction clicks, released at a rate of 15 per second, with 
a maximum of 700 stimulations and an analysis time of 
15msec. The passing band used was from 0 to 3,000 Hz. 
The stimuli started at 80 dB HL and progressively reduced 
until the waves totally disappeared. For the electrophy-
siological hearing threshold, we considered the lower 
stimulus intensity in which wave II could be noticed.
For graph creation and statistical analysis we used 
the GraphPad Prism 4.00.255 software. We assessed the 
sample distribution by means of the Komogorov-Smirnov 
methods. Results were expressed as mean ± mean standard 
error (MED ± PM), for continuous data and as median 
(Md) and minimum (Min) and maximum (Max) values for 
the original data. The minimum significance accepted was 
5%. The many experimental procedures were compared 
using the following tests:
Student t test (when possible, to be used with 
pairing): to compare the means of the distortion product 
otoacoustic emission for each frequency before and after 
treatment; compare the mean values of the electrophy-
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siological thresholds of the animals obtained through the 
brainstem evoked auditory potential between the first 
(D0) and the fourth (D3) days, for the control (saline) and 
24mg/kg for the cisplatin group.
The ANOVA variance analysis with Intergroup 
Significance established by the Tukey test: to compare 
the mean values of the electrophysiological thresholds of 
the animals obtained by means of the brainstem evoked 
auditory potential between the first (D0), fourth (D3) and 
the fifth (D4) days of assessment; compare the mean I-V 
interval values obtained through the brainstem evoked 
auditory potential between the first (D0), fourth (D3) and 
the fifth (D4) days of assessment.
RESULTS
Cisplatin-induced ototoxicity was confirmed by 
light microscopy under hematoxylin-eosin (HE) (paper 
submitted to publication).
Group 1 (CDDP 24 D3 DPEOAE) X Group 2 (C 24 
D3 DPEOAE).
There was a significant reduction in DPEOAE ampli-
tudes in the frequencies tested (3, 4, 6 and 8 kHz) between 
days D0 and D3, in the group that received CDDP at the 
dose of 24 mg/kg (Group 1). Such reduction was not seen 
in the control group. (Figs. 1 A, B, C and D).
In group 3, there was a high mortality among the 
animals assessed on D4 of the procedure. Of the eight 
animals which received CDDP at the cumulative dose of 
24 mg/kg, only 3 remained alive for DPEOAE on D4. Of 
these, 2 of 3 rats had their DPEOAE disappearing, proven 
by a signal/noise difference below 6 dB SPL, in the fre-
quencies of 3 and 4 kHz. One animal also did not show 
DPEOAE in the frequency of 6 kHz. At the frequency of 
8 kHz there was a significant reduction in DPEOAE am-
plitude between D0 and D4 (Fig. 2).
Figure 1. Graph of the DPEOAE amplitude expressed as mean and 
standard error in the average of days D0 and D3, in groups 1 and 2. 
The asterisks represent statistical significance. CDDP = cisplatin; C = 
control. Graph A: 3 kHz frequency (Test T: * p = 0.0095 - D3 x D0 CDDP). 
Graph B: 4 kHz frequency (Test T: * p = 0.0073 - D3 x D0 CDDP). Graph 
C: 6 kHz frequency (Test T: * p = 0.0284 - D3 x D0 CDDP). Graph D: 
8 kHz frequency (Test T: * p = 0.0338 - D3 x D0 CDDP).
Group 3 (CDDP 24 D4 DPEOAE) X Group 4 (C 24 
D4 DPEOAE)
Figure 2. Graph showing DPEOAE amplitudes expressed as mean 
and error deviation of the average values in days D0 and D4, in groups 
3 and 4 at the frequency of 8 kHz. The asterisk represents statistical 
significance. CDDP = cisplatin; C = control. T Test: * p = 0.0459 (D4 
x D0 CDDP).
Figure 3. Graph showing DPEOAE amplitudes expressed as mean and 
error deviation of the average values in days D0 and D3, in groups 5 
and 6. CDDP = cisplatin; C = control. There was no statistical meaning 
in any of the groups (T Test: p > 0.05).
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Group 5 (CDDP 16 D3 DPEOAE) X Group 6 (C 16 
D3 DPEOAE)
At the dose of 16 mg/kg of CDDP, it was not pos-
sible to identify statistically significant reduction in mean 
DPEOAE amplitudes between D0 and D3, in all the fre-
quencies investigated (p > 0.05) (Figs. 3 A, B, C and D).
Group 7 (CDDP 16 D4 DPEOAE) X Group 8 (C 16 
D4 DPEOAE)
As it happened on the 3 day assessment at the dose 
of 16 mg/kg of CDDP, it was not possible to identify a 
statistically significant reduction on the mean amplitudes 
of DPEOAE between D0 and D4, in all the frequencies 
investigated (p > 0.05) (Figs. 4 A, B, C and D).
Figure 4. Graph showing DPEOAE amplitudes expressed as mean and 
error deviation of the average values in days D0 and D4, in groups 7 
and 8. CDDP = cisplatin; C = control. There was no statistical meaning 
in any of the groups (T Test: p > 0.05).
Group 9 (CDDP 24 BEAP) X Group 10 (C 24 BEAP)
There was a significant increase in the mean electro-
physiological threshold of animals injected with 24mg/kg 
of cisplatin on D3 and D4 when compared to D0. We did 
not notice statistically significant differences considering 
these thresholds between D3 and D4 when compared to 
D0. We did not notice statistically significant differences in 
these thresholds between D3 and D4. In the control group, 
there was no increase in electrophysiological thresholds 
(Fig. 5). We did not find statistically significant difference 
of the I-V interval among the days in both groups (Fig.6).
Group 11 (CDDP 16 BEAP) X Group 12 (C 16 BEAP)
We found a significant increase in the mean elec-
trophysiological threshold of the animals injected with 16 
mg/kg of cisplatin at D3 when compared to D0. We did 
not notice significant difference in these two thresholds 
between D3 and D4. In the control group there was also 
no raise in the electrophysiological thresholds (Fig. 7). 
We also did not find statistically significant difference in 
the I-V interval between the days in both groups (Fig. 8).
Figure 5. Graph of the mean electrophysiological thresholds in groups 
9 and 10 at D0, D3 and D4, expressed as mean and mean standard 
error (MED and EPM). The asterisk represents a statistically significant 
difference. CDDP = cisplatin; C = control. ANOVA - Tukey: * p < 0.01 
(D3 x D0 CDDP); * p < 0.001 (D4 x D0 CDDP).
Figure 6. Graph showing the mean I-V interval of the animals in groups 
9 and 10 at days D0, D3 and D4 expressed as mean and mean stan-
dard error (MED and [IEY1] EPM). We did not find statistical difference 
between days in the two groups. ANOVA p > 0.05.
DISCUSSION
In this experiment only the right side temporal bone 
would be used for the different procedures, in order to 
make more homogeneous the time between cochlear re-
moval and its fixation, thus avoiding damaging the organ to 
the utmost associated with its removal, which was carried 
out by the author only. Morphological evaluation data by 
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light microscopy will be published in another paper. The 
animals submitted to BEAP did not have their cochleas 
removed, and therefore could be assessed on the third 
and fourth days after the procedure started. That is why 
it is necessary to have four groups for BEAP assessments 
and 8 for DPEOAE. 
The intraperitoneal administration route used in this 
study proved efficient to trigger ototoxicity in the doses 
used. This is also the systemic administration route seen in 
most ototoxicity experiments with CDDP in rats. However, 
other routes can be used such as the arterial33, venous34, 
subcutaneous35 and intramuscular15.
DPEOAE are a hearing assessment method which 
represents the outer hair cell function, one of the main 
cisplatin-damaged targets36. DPEOAE execution protocol in 
animal experiments bear little variability, with the greatest 
controversy happening around the possibility of keeping 
constant an F1 and F2 stimulus intensity30,32 or variable36,37 
for the Dpgram type of acquisition. The possible frequen-
cies to be studied through DPEOAE vary among the species 
of animals. Hyppolito et al.32 identified its presence from 
1.5 kHz in guinea pigs; Hatzopoulos et al.37, studied them 
in Sprague-Dawley rats, beyond 4 kHz; Lopez-Gonzalez 
et al.36, in Wistar rats, identified them between 1 and 6 
kHz; Sockalingan et al.30, in albino rats, between 2 and 
8 kHz for a signal/noise ratio ≥ 3 dB SPL. McAlpine and 
Johnstone38 found CDDP ototoxicity through DPEOAE 
with I/O function shape fixing the frequency in 8 kHz. 
In the present investigation, we carried out the protocol 
with a fixed intensity of 70 dB SPL, attaining measurable 
responses from 3 kHz for a signal/noise ratio ≥ 6 dB SPL 
as established by the technical specifications of the device 
used (Madsen-Capella).
In the present study, only the 24 mg/kg dose was 
able to trigger a DPEOAE measurable cisplatin-induced 
ototoxicity in all the frequencies evaluated. With D3 as-
sessment, differently from the control group, there was a 
significant reduction in DPEOAE amplitude in the treated 
group. At D4, there was no response or amplitude re-
duction. In the animals treated with 16 mg/kg, although 
there was a DPEOAE reduction in the 3, 4, 6 and 8 kHz 
frequencies after CDDP treatment both in D3 and D4, it 
was not possible to show statistical significance. This can 
be explained by the large individual variability in response 
to ototoxicity by CDDP in rats for doses ≥ 15 mg/kg in 
bolus infusion, yielding a greater amplitude standard de-
viation in otoacoustic emissions in the samples, reducing 
the statistical tests power. This variability is followed of 
different levels of plasma concentration of the drug when 
injected in the vein or peritoneum37. Sockalingam et al.30 
also did not show DPEOAE significant reductions in rats 
after 72h for the dose of 12 mg/kg of CDDP. Hatzopoulos 
et al.37 found a significant reduction in the signal/noise 
ratio (S/N) of DPEOAE for the frequencies of 6,34, 7,13 
and 7,56 kH, and it was not seen for 4, 5 or 8 kHz. It is 
worth stressing that in this last experiment, the parameter 
assessed was the S/N ratio and not the otoacoustic emis-
sions amplitude alone. Lopez-Gonzalez et al.36, used a 
lower CDDP dose (10 mg/kg), and noticed a significant 
reduction in DPEOAE in Wistar rats between 1 and 6 kHz 
as of the seventh day of assessment, returning to initial 
values after 30 days. Hyppolito et al.31, in their study with 
albino guinea pigs using 24 mg/kg found no DPEOAE in 
Figure 7. Graph of the mean electrophysiological thresholds in groups 
11 and 12 at D0, D3 and D4, expressed as mean and mean standard 
error (MED and [IEY2] EPM). The asterisk represents a statistically 
significant difference. CDDP = cisplatin; C = control. ANOVA - Tukey: 
* p < 0.05 (D3 x D0 CDDP).
Figure 8. Graph of the mean I-V interval of the animals in groups 11 and 
12 at days D0, D3 and D4 expressed as mean and mean standard error 
(MED and  [IEY3]EPM). We did not find statistical difference among 
the days of the 2 groups. ANOVA p > 0.05.
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100% of the animals treated and assessed on the third day 
after its onset. We did not find rat studies with 24 mg/kg 
of CDDP. The papers showing DPEOAE reduction after 
CDDP injection in rats either used a longer assessment time 
with lower doses36 or did not use DPEOAE amplitude as 
an assessment parameter, but rather the S/N ratio37. This 
type of analysis raises the experiment bias, since the noise 
detected in the external auditory canal of the animals can 
be influenced by external factors, such as respiratory noi-
ses39. Therefore, in the present study, we chose to assess 
DPEOAE amplitude and not S/N ratio, for a maximum of 
96h after treatment, because of the high animal mortality 
after this time with the doses of 16 or 24 mg/kg.
Thus, in the present investigation, the DPEOAE 
were able to identify cisplatin-induced ototoxicity in rats 
only with the 24mg/kg dose.
The brainstem evoked auditory potentials have been 
broadly used to study cisplatin-induced ototoxicity in ro-
dents22,28-30,33-35,37,40-50. However, there is no exam technique 
standardization among the many authors.
In the present study we could notice a BEAP trace 
in Wistar rats with the identification of 5 to 7 waves, and 
wave II had the highest amplitude. For that, we used 
needle-shaped platinum electrodes, placed on the vertex 
subdermal (positive or active electrode), right side re-
troauricular region (reference or negative electrode and 
nasal tip (ground electrode). The ground electrode may 
be placed anywhere in the body without altering the trace. 
Different positions of the reference and active electrodes 
make some waves more or less evident51. Amsallem and 
Andrieu-Guitrancourt34 placed the electrodes between 
the vertex (active) and tail (reference); Li et al.52 between 
the vertex (positive) and neck muscles (negative). Many 
authors of the same research group published studies posi-
tioning the electrodes at the vertex (positive) and nasal tip 
(negative)28,29,43-45,48,49,53. In other studies, especially the most 
recent ones, the electrodes were placed at reference points 
similar to those used in the current experiment22,33,37,42,46,50. 
It is believed that in the clinical records this location be 
the one that offers an ideal BEAP trace54.
There is controversy regarding how to establish the 
electrophysiological threshold in rats by means of BEAP. 
In agreement with Amsallem and Andrieu-Guitrancourt41, 
this study showed that wave II is the one with the greatest 
amplitude in rats and the last one to disappear with the 
reduction in the sound stimulus intensity. Therefore, this 
wave was the parameter used to establish the auditory 
threshold in the animals. Kamimura et al.28 also conside-
red wave II in order to establish the electrophysiological 
threshold. According to Hatzopoulos et al.42, wave III is 
the one with the greatest visibility and reproducibility, 
thus being the one that establishes the electrophysiological 
threshold. Tanaka, Whitworth e Rybak48 had two repli-
cable peaks as parameters for any wave, while Minami, 
Sha and Schacht50, considered waves III or IV. Others still 
establish the threshold by means of visually detectable 
and reproducible traces, without specifying any wave 
type of quantity52,55.
The number of stimuli necessary to trigger repro-
ducible BEAP traces varies between 12830 and 102430,33,50 
in rat experiments.  The rate of stimuli presentation varies 
between 5 per second 28,29,43-45,48,53 and 20 per second30,46. 
In the present investigation we could see reproducible 
responses using a stimuli rate of 15 per second for 300 
to 700 stimuli.
Anther variable parameter is the type of stimuli used. 
Most of the authors prefer the tone burst, with or without 
clicks22,28,29,33,37,42,44-50,52,53. The tone burst has the advantage 
of assessing hearing in a frequency-specific way. Its use 
is important when one wishes to differentiate whether the 
lesion affects the cochlear areas responsible for lower or 
higher frequencies. However, the higher the number of 
tone bursts used, the longer the test becomes, increasing 
the mortality risk in animal experiments because of a 
longer anesthesia time. The click stimulus establishes a 
physiological response that represents a hearing frequency 
range between 1000 and 4000 Hz51. With that, it triggers 
a greater nerve fiber depolarization synchronism, making 
the trace more constant and reproducible than other types 
of stimuli56. Thus, similarly to what happens in other stu-
dies30,34,41, this experiment was performed using only the 
rarefaction click as a stimulus.
Although the responses triggered by the click are 
represented on the cochlear middle turn in rats and not in 
the basal turn57 - a site where the cisplatin-induced lesion 
prevails28,48,50,55,58, the 16 e 24 mg/kg doses of cisplatin were 
able to cause BEAP-measurable ototoxicity. The mean 
increase in the electrophysiological threshold for the 24 
mg/kg dose was of 12 dB HL on D3 and 21 dB HL on D4. 
However, there was no statistically significant difference 
between D3 and D4. The 16 mg/kg dose caused a mean 
threshold increase of 14.17 dB HL both at D3 and D4, 
with this last day of assessment, having greater threshold 
variability secondary to increased animal mortality. There 
was no variation in BEAP threshold in the control group. 
The mean increase in the electrophysiological threshold 
for clicks after 16 mg/kg of cisplatin infusion and 72h as-
sessment varied in the literature between 15.2 dB42 and 
36 dB44. Sockalingam et al.30 did not show a significant 
threshold increase for clicks after 3 days, with the dose 
of 12 mg/kg. On the other hand, Tanaka, Whitworth and 
Rybak48 showed an average increase of 18.3 dB for the 
dose of 13 mg/kg. We did not find BEAP studies in the 
hearing assessment of rats for the doses of 24 mg/kg.
Through BEAP there was also a cisplatin-triggered 
hearing lesion from cochlear structures, since there was no 
significant increase in the I-V interval in treated animals. 
A similar result was seen by Rebert, Pryor and Frick41. In 
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hamsters, Church et al.59 showed I-IV interval stretching 
with the dose of 15 mg/kg of CDDP, suggesting a retro-
cochlear lesion for this drug.
Therefore, brainstem evoked auditory potentials 
(BEAP), using rarefaction clicks as auditory stimuli was 
an efficient method to detect CDDP ototoxicity in rats in 
the two doses employed. It is possible that this finding be 
associated with a great variability (standard deviation) of 
the DPEOAE amplitudes among the animals investigated.
CONCLUSIONS
BEAPs were more sensitive than DPEOAE in detec-
ting cisplatin-induced ototoxicity in rats in different doses 
and means of administration.
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